Susquehanna Fundamental Investments LLC Buys Shares of 192,563 Denali Therapeutics Inc. (NASDAQ:DNLI)

Susquehanna Fundamental Investments LLC purchased a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 192,563 shares of the company's stock, valued at approximately $3,924,000. Susquehanna Fundamental Investments LLC owned about 0.13% of Denali Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Sterling Capital Management LLC raised its holdings in shares of Denali Therapeutics by 589.9% in the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after buying an additional 1,516 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in Denali Therapeutics by 30.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock worth $77,000 after acquiring an additional 885 shares during the period. KBC Group NV grew its stake in Denali Therapeutics by 75.8% during the 4th quarter. KBC Group NV now owns 6,334 shares of the company's stock valued at $129,000 after purchasing an additional 2,731 shares during the last quarter. AlphaQuest LLC increased its holdings in shares of Denali Therapeutics by 177.1% in the fourth quarter. AlphaQuest LLC now owns 6,961 shares of the company's stock valued at $142,000 after purchasing an additional 4,449 shares during the period. Finally, E Fund Management Co. Ltd. raised its stake in shares of Denali Therapeutics by 32.2% in the fourth quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock worth $204,000 after purchasing an additional 2,436 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company's stock.

Denali Therapeutics Stock Up 2.4 %

Shares of NASDAQ DNLI traded up $0.38 during trading on Friday, hitting $16.44. The company had a trading volume of 1,118,564 shares, compared to its average volume of 1,085,462. The firm has a market capitalization of $2.39 billion, a price-to-earnings ratio of -5.96 and a beta of 1.58. The stock has a fifty day simple moving average of $14.57 and a two-hundred day simple moving average of $20.58. Denali Therapeutics Inc. has a fifty-two week low of $10.57 and a fifty-two week high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, topping analysts' consensus estimates of ($0.75) by $0.08. On average, analysts anticipate that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on DNLI shares. The Goldman Sachs Group cut their price target on shares of Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating on the stock in a report on Tuesday, January 28th. Cantor Fitzgerald upgraded shares of Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Thursday, April 10th. Robert W. Baird assumed coverage on Denali Therapeutics in a research report on Tuesday, January 7th. They set an "outperform" rating and a $31.00 price target on the stock. Morgan Stanley assumed coverage on Denali Therapeutics in a research note on Friday, March 7th. They set an "overweight" rating and a $33.00 price objective for the company. Finally, Oppenheimer lowered their target price on Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating on the stock in a research note on Monday, March 3rd. One analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $37.57.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.